Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001113423-17-000031
Filing Date
2017-11-08
Accepted
2017-11-08 17:11:39
Documents
6
Period of Report
2017-09-30

Document Format Files

Seq Description Document Type Size
1 6-K q3-2017x6k.htm 6-K 20401
2 EXHIBIT 99.1 q3-2017xex991fsxquarterly.htm EX-99.1 822442
3 EXHIBIT 99.2 q3-2017xex992mdaxquarterly.htm EX-99.2 382246
4 EXHIBIT 99.3 q3-2017xex993certification.htm EX-99.3 12573
5 EXHIBIT 99.4 q3-2017xex994certification.htm EX-99.4 12609
6 aeternazentarislogoa53.jpg GRAPHIC 14150
  Complete submission text file 0001113423-17-000031.txt   1271062
Mailing Address C/O NORTON ROSE FULBRIGHT CANADA LLP 1 PLACE VILLE MARIE, SUITE 2500 MONTREAL A8 H3B 1R1
Business Address C/O NORTON ROSE FULBRIGHT CANADA LLP 1 PLACE VILLE MARIE, SUITE 2500 MONTREAL A8 H3B 1R1 843-900-3201
Aeterna Zentaris Inc. (Filer) CIK: 0001113423 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-38064 | Film No.: 171187476
SIC: 2834 Pharmaceutical Preparations